History of Aurobindo Pharma Limited (APL)

_x000D_ Founded in 1986, Aurobindo Pharma Limited (APL) is a pharmaceutical company that is involved in the development, manufacture and sale of Active Pharma Ingredients (API) and formulations._x000D_ _x000D_ The company started their operations in 1988-1989 with a single manufacturing unit at Pondicherry to manufacture Semi Synthetic Penicillins (SSPs).  Between 1992-1993, they set up another manufacturing facility in Hyderabad to manufacture CMIC Chloride, a bulk drug intermediate. In 1994, the company merged with Chaitanya Organics Pvt. Ltd and started the commercial production of the pharmaceutical formulation unit. In 1995, Aurobindo Pharma Limited went public. Since then, the company has expanded its product base and started manufacturing various formulations._x000D_ _x000D_ From  2003 to 2004, the company set up a subsidiary in China and started commercial production. Between 2005 to 2006, Aurobindo Pharma Limited acquired UK-based Milpharm Limited, which is involved in marketing generic formulations in the UK market. They established their presence worldwide in Brazil, the USA, Puerto Rico and Portugal._x000D_ _x000D_ As of March 2023, Aurobindo Pharma Limited has 25 State-of-the-art manufacturing and packaging facilities, with export presence in more than 150 countries, 9 R&D centres and over 1,500 scientists and analysts involved in R&D activities._x000D_

Business Segments of Aurobindo Pharma Limited 

_x000D_

_x000D_
• API: Under this segment, Aurobindo Pharma Limited develops and manufactures APIs. Their five manufacturing units are inspected and approved by the US FDA, ANVISA, TGA Australia, UK MHRA and other trusted regulatory agencies.
_x000D_

_x000D_

_x000D_
• Antiretroviral (ARV): Under this, the company works with an aim to offer a wide range of high-quality antiretroviral drugs (US FDA Approved) for PLHIV & CLHIV.
_x000D_

_x000D_

_x000D_
• AuroZymes: This is the biocatalysts division of APL that develops and produces biocatalysts that can be utilised in the Chemical and Pharmaceutical Industries.
_x000D_

_x000D_

_x000D_
• Custom Synthesis: In this segment, the company provides customer-centric project-based chemistry services through their custom research and manufacturing division, AuroSource.
_x000D_

_x000D_

_x000D_
• Formulations: Under this segment, APL is involved in cost-effective drug development and substantial manufacturing.
_x000D_

_x000D_

_x000D_
• Peptides: In this segment, the company develops peptide-based generic APIs, specifically focusing on diabetology and oncology segments.
_x000D_

_x000D_

_x000D_
• R&D: The R&D segment of the company is involved in developing new drug delivery systems and new dosage formulations.
_x000D_

_x000D_ As of March 31, 2023, some of the subsidiaries of Aurobindo Pharma Limited are as follows:_x000D_

_x000D_
• Helix Healthcare B.V.: This subsidiary of the company is involved in the healthcare sector.
_x000D_
• Aurovitas Pharma Polska: This is a wholly-owned subsidiary of the company that focuses on generic, Rx and OTC drugs covering 22 therapeutic areas.
_x000D_
• Milpharm Limited: This wholly-owned subsidiary of the company that manufactures pharma products.
_x000D_

_x000D_

Key Personalities of Aurobindo Pharma Limited

_x000D_ Nityananda Reddy, Managing Director and Chairman_x000D_ _x000D_ Nityananda Reddy is the Chairman and Managing Director of Aurobindo Pharma Limited. He has been associated with APL since its initial days. He has experience in manufacturing technology and oversees the overall affairs of the company._x000D_

Corporate Actions of Aurobindo Pharma Limited

_x000D_ The company issued a bonus share of a 1:1 ratio with a record date of July 21, 2015.